Kyowa Hakko Kirin will continue to strive to be a “Japan-based world-leading R&D type life science company” contributing to the health and comfort of people around the world

The Kyowa Hakko Kirin Group provides high-quality products and services that meet various medical needs by making full use of our unique business structure, where pharmaceutical business associating with biosimilar, diagnostic reagents and bio-chemical businesses. Its core company, Kyowa Hakko Kirin, will be a Japan-based Global Specialty Pharmaceutical Company contributing to human health and well-being worldwide through innovative drug discovery and global commercialization, driven by state-of-the-art antibody technologies.

 

In the five-year Mid-term Business Plan formulated in 2016, we are striving to achieve outstanding growth through the implementation of the four core strategies under the theme of “Leaping Forward for Global Specialty Pharmaceutical Company”: “Improvement of Global Competitiveness,” “Creating Innovation,” “Continuous Improvement for Operational Excellence” and “Contribution to Health and Well-being of People.” In this FY2016-2020 Mid-term Business Plan, one of our goals is to globally commercialize our original drugs having an utterly new mechanism of action. Accordingly, we expect that the achievement of this goal will contribute to the demands of patients, their families and healthcare professionals suffering from a disease for which no effective treatment currently exists.

 

To this end, we will put more effort into further progress of our R&D capabilities, as well as our technological competence, as our strengths. We will also work on creating innovation in the areas where our Group’s findings and knowhow are fully utilized. Thus, we will strive to challenge for continuous creation of potent drugs to have a new mechanism and satisfy unmet medical needs.

Furthermore, toward the organization where personnel varied in personality respect one another for maximization of their capabilities, we have been proactively improving our working environment with a focus on diversity. Needless to say, for the realization and development of our Group’s vision, it is essential for all of us to be mentally and physically healthy prior to doing our utmost.

 

The Kyowa Hakko Kirin Group aims to be reliable life sciences companies for every stakeholder by sincerely fulfilling our corporate social responsibilities, including commitments to transparency, fairness and compliance.
I would like to ask for your continued support now and in the future.

 

Executive Director of the Board
President and Chief Executive Officer
Nobuo Hanai